⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ZLAB News
Zai Lab Limited American Depositary Shares
Form 8-K
sec.gov
ZLAB
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
businesswire.com
ZLAB
Zai Lab Receives China NMPA Approval of TIVDAK ® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
businesswire.com
ZLAB
Zai Lab Announces Changes to Senior Leadership Team
businesswire.com
ZLAB
Form 8-K
sec.gov
ZLAB
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
businesswire.com
ZLAB
Form 8-K
sec.gov
ZLAB
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
businesswire.com
ZLAB
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
businesswire.com
ZLAB
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
businesswire.com
ZLAB